Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin

Eleven patients with advanced basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) of the skin were treated with cis‐diamminedichloroplatinum II (cisplatin) and doxorubicin. Seven patients had prior surgery and six of these seven had prior radiation therapy. All patients had an adequate trial...

Full description

Saved in:
Bibliographic Details
Published inCancer Vol. 55; no. 8; pp. 1629 - 1632
Main Authors Guthrie, Troy H., McElveen, Leland J., Porubsky, Edward S., Harmon, John D.
Format Journal Article
LanguageEnglish
Published New York Wiley Subscription Services, Inc., A Wiley Company 15.04.1985
Wiley-Liss
Subjects
Aged
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Carcinoma, Basal Cell - drug therapy
Carcinoma, Squamous Cell - drug therapy
Chemotherapy
Cisplatin - administration & dosage
Doxorubicin - administration & dosage
Female
Follow-Up Studies
Humans
Male
Medical sciences
Middle Aged
Nausea - chemically induced
Neoplasm Recurrence, Local
Pharmacology. Drug treatments
Skin Neoplasms - drug therapy
Antineoplastic agent
Human
Squamous cell carcinoma
Skin disease
Basal cell carcinoma
Chemotherapy
Polychemotherapy
Treatment
Advanced stage
Tumor
Anthracyclins
Skin
Platinum II Complexes
Online AccessGet full text

Cover

More Information
Summary:Eleven patients with advanced basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) of the skin were treated with cis‐diamminedichloroplatinum II (cisplatin) and doxorubicin. Seven patients had prior surgery and six of these seven had prior radiation therapy. All patients had an adequate trial of chemotherapy. One patient received a second course of chemotherapy after relapse. Responses were seen in 10 of 12 (87%) of chemotherapy courses, and 5 of 11 patients (46%) have an unmaintained complete remission lasting 2 to 31 months. Toxicity was acceptable and consisted primarily of gastrointestinal side effects. These results indicate the combination of cisplatin and doxorubicin has significant activity in both advanced BCC and SCC of the skin. In addition, a portion of patients treated with the combination achieve a long‐term unmaintained disease‐free state.
Bibliography:Fellow in Medical Oncology.
Associate Professor of Medicine, Section of Otolaryngology.
Assistant Professor of Medicine, Section of Medical Oncology/Hematology.
Professor of Medicine, Chairman, Section of Otolaryngology.
ISSN:0008-543X
1097-0142
DOI:10.1002/1097-0142(19850415)55:8<1629::AID-CNCR2820550802>3.0.CO;2-I